Our results reveal a mechanism linking SMARCA4/2 loss to chemoresistance by inhibiting apoptosis induction and suggest a potential therapeutic strategy for improving treatment for SMARCA4/2-deficient cancers. The gene discussed is SMARCA4; the disease is cancer.